295 related articles for article (PubMed ID: 20226194)
1. Design of an optimized scaffold for affibody molecules.
Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
[TBL] [Abstract][Full Text] [Related]
2. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
3. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
[TBL] [Abstract][Full Text] [Related]
4. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
Vernet E; Konrad A; Lundberg E; Nygren PA; Gräslund T
J Immunol Methods; 2008 Sep; 338(1-2):1-6. PubMed ID: 18671978
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for molecular recognition in an affibody:affibody complex.
Lendel C; Dogan J; Härd T
J Mol Biol; 2006 Jun; 359(5):1293-304. PubMed ID: 16750222
[TBL] [Abstract][Full Text] [Related]
6. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
Ekblad T; Tolmachev V; Orlova A; Lendel C; Abrahmsén L; Karlström AE
Biopolymers; 2009; 92(2):116-23. PubMed ID: 19140162
[TBL] [Abstract][Full Text] [Related]
8. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
Orlova A; Tolmachev V; Pehrson R; Lindborg M; Tran T; Sandström M; Nilsson FY; Wennborg A; Abrahmsén L; Feldwisch J
Cancer Res; 2007 Mar; 67(5):2178-86. PubMed ID: 17332348
[TBL] [Abstract][Full Text] [Related]
9. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
10. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.
Jonsson A; Wållberg H; Herne N; Ståhl S; Frejd FY
Biotechnol Appl Biochem; 2009 Aug; 54(2):93-103. PubMed ID: 19545237
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
14. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
Ahlgren S; Andersson K; Tolmachev V
Nucl Med Biol; 2010 Jul; 37(5):539-46. PubMed ID: 20610158
[TBL] [Abstract][Full Text] [Related]
15. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
16. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
Grimm S; Salahshour S; Nygren PÅ
N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of Affibody ligands to the transcription factor c-Jun.
Lundberg E; Brismar H; Gräslund T
Biotechnol Appl Biochem; 2009 Jan; 52(Pt 1):17-27. PubMed ID: 18260830
[TBL] [Abstract][Full Text] [Related]
18. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamics of folding and binding in an affibody:affibody complex.
Dogan J; Lendel C; Härd T
J Mol Biol; 2006 Jun; 359(5):1305-15. PubMed ID: 16701696
[TBL] [Abstract][Full Text] [Related]
20. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules.
Renberg B; Shiroyama I; Engfeldt T; Nygren PK; Karlström AE
Anal Biochem; 2005 Jun; 341(2):334-43. PubMed ID: 15907880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
